Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3362738 | 0.89 | MAPT (0.75) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL13809595 | 0.82 | MAPT (0.63) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL14267957 | 0.80 | MAPT (0.64) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL16029701 | 0.79 | MAPT (1.00) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL14363096 | 0.79 | ALDH1A1 (0.51) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL3063864 | 0.78 | MAPT (0.65) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL21067641 | 0.78 | MAPT (0.65) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL10405791 | 0.78 | HSD17B10 (0.72) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL3363633 | 0.76 | ALDH1A1 (0.58) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL15996807 | 0.75 | MAPT (0.50) | MAPTALDH1A1KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010259-A1 | Methods of Treating an Overweight or Obese Subject | ZAFGEN, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010259-A1 | Methods of Treating an Overweight or Obese Subject | METAP2, METAP1, ACER2 | MAPT 3100/4885ALDH1A1 802/4885KMT2A 444/4885 |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | GABRA5, GABRA4, GABRA3 | MAPT 1578/4885ALDH1A1 372/4885KMT2A 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.